Polaris Group Stock

6550

KYG7171A1085

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 2026-01-19			5-day change	1st Jan Change
32.05 ^TWD	-1.99%		+3.55%	+3.05%

Dec. 26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
Dec. 26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI

The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Companyâs core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 12 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-01-19	32.05 NT$	-1.99%	1,143,906
26-01-16	32.70 NT$	-1.21%	1,675,266
26-01-15	33.10 NT$	+0.46%	1,192,620
26-01-14	32.95 NT$	+4.77%	2,832,943
26-01-13	31.45 NT$	+1.62%	1,807,214

End-of-day quote Taiwan S.E., January 18, 2026

More quotes

Income Statement and Estimates

More financial data

Capitalization	23.96B 759M 652M 605M 565M 1.05B 68.97B 1.13B 6.99B 2.75B 32.84B 2.85B 2.79B 120B	P/E ratio 2023	-35.6x	P/E ratio 2024	-13.6x
Enterprise value	23.97B 759M 652M 605M 565M 1.05B 69B 1.13B 6.99B 2.75B 32.85B 2.85B 2.79B 120B	EV / Sales 2023	7,151,545,988x	EV / Sales 2024	318,439,381x
Free-Float	35.26%	Yield 2023 *	-	Yield 2024	-

Dec. 26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
Dec. 26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI
Dec. 25	Polaris Group announced that it expects to receive TWD 3.2 billion in funding	CI
Dec. 16	Polaris Group's CEO Resigns	MT
Dec. 16	Polaris Group Announces Resignation of Steve J.P. Hsu as Chief Executive Officer, Effective December 24, 2025	CI
Dec. 16	Polaris Group Names New Chairman; Shares Rally 10%	MT
Dec. 15	Polaris Group Announces Management Changes, Effective December 24, 2025	CI
Nov. 12	Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-01	Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-19	Polaris Cancer Drug Candidate Enters FDA Substantive Review	MT
25-07-21	Polaris Unit Grants Drug Distribution Rights to Bioprofarma Bago	MT
25-06-11	Polaris Group Completes Submission of US FDA Application for Rare Lung Cancer Drug	MT
25-06-10	Polaris Group Completes Rolling Submission of Biologic License Application for ADI-PEG 20 with FDA to Treat Malignant Pleural Mesothelioma	CI

23-12-21	Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth	GL
23-12-04	Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	AQ
23-12-04	Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	GL
23-11-29	Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study	GL
23-11-16	Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	GL

1 day	-1.99%
1 week	+3.55%
Current month	+3.05%
1 month	+2.89%
3 months	-10.97%
6 months	-15.32%
Current year	+3.05%

1 week	31.55	33.95
1 month	29.7	33.95
Current year	29.7	33.95
1 year	26.35	52
3 years	26.35	107.5
5 years	15.3	232
10 years	9.5	232

Polaris Group Stock

Equities

6550

KYG7171A1085

Biotechnology & Medical Research

Valuation: Polaris Group

Chart: Polaris Group

Latest news: Polaris Group

Press Releases: Polaris Group

Quotes and Performance

Course Extremes

Managers and Directors: Polaris Group

ETFs: Polaris Group

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Manager	Title	Age	Since
Lan Ying Huang DFI	Director of Finance/CFO	-	2019-02-28
Wei Yuan Lin COO	Chief Operating Officer	-	2019-01-31
Shao Chen Chen CEO	Chief Executive Officer	-	2014-04-30

Director	Title	Age	Since
Hung Wen Chen CHM	Chairman	-	2014-11-23
Shao Chen Chen BRD	Director/Board Member	-	2020-02-24
Wei Yuan Lin BRD	Director/Board Member	-	2020-01-02

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
POLARIS GROUP	-1.99%	+3.55%	-26.15%	-64.39%	797M
LONZA GROUP AG	-2.36%	-3.50%	-3.05%	+11.52%	48.93B
IQVIA HOLDINGS INC.	-1.49%	-1.32%	+20.43%	+6.92%	40.48B
BEONE MEDICINES AG	-0.03%	+1.26%	+60.98%	+23.20%	37.42B
CELLTRION, INC.	-0.71%	-3.69%	+20.76%	+39.16%	31.03B
REVOLUTION MEDICINES, INC.	-2.43%	+2.65%	+198.54%	+335.64%	23.25B
MEDPACE HOLDINGS, INC.	-1.16%	+1.95%	+81.09%	+166.96%	17.21B
Average	-1.45%	+0.40%	+50.37%	+74.14%	28.45B
Weighted average by Cap.	-1.39%	-0.10%	+48.18%	+68.07%

	2023	2024
Net sales	7.48 0.24 0.2 0.19 0.18 0.33 21.53 0.35 2.18 0.86 10.25 0.89 0.87 37.47	107 3.39 2.91 2.7 2.52 4.7 307.98 5.05 31.21 12.29 146.64 12.71 12.45 535.86
Net income	-1.58B -49.94M -42.9M -39.8M -37.19M -69.23M -4.54B -74.39M -460M -181M -2.16B -187M -183M -7.9B	-2.5B -79.27M -68.09M -63.18M -59.02M -110M -7.2B -118M -730M -287M -3.43B -297M -291M -12.53B
Net Debt	-2.71B -85.69M -73.6M -68.29M -63.8M -119M -7.79B -128M -789M -311M -3.71B -321M -315M -13.55B	9.19M 291K 250K 232K 217K 404K 26.46M 434K 2.68M 1.06M 12.6M 1.09M 1.07M 46.03M